Member access

4-Traders Homepage  >  Shares  >  Amex  >  Protalix BioTherapeutics Inc.    PLX   US74365A1016

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Amex
08/22/2014 08/25/2014 08/26/2014 08/27/2014 08/28/2014 Date
2.44(c) 2.4(c) 2.45(c) 2.41(c) 2.61(c) Last
149 786 402 284 343 468 343 829 1 144 779 Volume
0.00% -1.64% +2.08% -1.63% +8.30% Change
More quotes
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Its... 
Surperformance© rating of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More about the company
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 40,2 M
EBIT 2014 -13,4 M
Net income 2014 -1,28 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 15,5x
Capi. / Sales 2014 6,09x
Capitalization 244 M
More Financials
Latest news on PROTALIX BIOTHERAPEUTICS I
1d ago PROTALIX BIOTHERAPEUTICS : Announces Conference Call to Discuss ELELYSO Pediatri..
07/24 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
07/24 PROTALIX BIOTHERAPEUTICS : Names Shlomo Yanai as Chairman of the Board of Direct..
06/27 PROTALIX BIOTHERAPEUTICS : Regulation FD Disclosure (form 8-K)
06/27 PROTALIX BIOTHERAPEUTICS : Announces New Data on ELELYSO(TM) (taliglucerase alfa..
06/23 PROTALIX BIOTHERAPEUTICS : Announces New Data on ELELYSO(TM) (taliglucerase alfa..
06/18 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
06/18 PROTALIX BIOTHERAPEUTICS : Initiates Phase II Study With PRX-112, an Orally-Admi..
06/13 PROTALIX BIOTHERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
06/13 PROTALIX BIOTHERAPEUTICS' : President and Chief Executive Officer, David Aviezer..
05/30 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
05/30 PROTALIX BIOTHERAPEUTICS : Announces ELELYSO(TM) (taliglucerase alfa) Approved i..
More news
Comments 
Advertisement
Income Statement Evolution
Protalix BioTherapeutics I : Income Statement Evolution
More Financials
EPS Revisions
Protalix BioTherapeutics I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF